Latest News
Category: ASX
Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the treatment of ovarian and lung...
Read more
Telix is pleased to announce that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen and Medizintechnik Aktiengesellschaft to acquire a licensed radiopharmaceutical production facility in Seneffe,...
Read more
Telix is pleased to share the company had a pre-NDA meeting with the United States Food and Drug Administration (FDA) on the 24th of July to discuss the Company’s plan...
Read more
Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June...
Read more
Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan...
Read more
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6...
Read more
Telix Pharmaceuticals Limited is pleased to provide its Annual Report...
Read more
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January...
Read more
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised...
Read more
Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50...
Read more